Table 1

Baseline features at presentation and therapy in 52 patients with antineutrophil cytoplasmic antibodies-associated vasculitis

Variable

Result


Diagnosis

Granulomatosis with polyangiitis

33 (63.5)

Microscopic polyangiitis

11 (21.2)

Renal limited vasculitis

8 (15.4)

ANCA

Proteinase 3 ANCA

30 (57.7)

Myeloperoxidase ANCA

22 (42.3)

Disease activity

Median BVAS

15.0 (12.0 to 23.5)

Median C-reactive protein level (mg/l)

37.0 (11.5 to 81.5)

Disease manifestations

Renal involvement

39 (75.0)

Systemic manifestations

32 (61.5)

Ear, nose and throat involvement

28 (53.8)

Pulmonary involvement

22 (42.3)

Arthritis/joint pain

18 (34.6)

Peripheral neuropathy

15 (28.8)

Eye involvement

13 (25.0)

Cutaneous vasculitis

12 (23.1)

Pulmonary involvement

Pulmonary nodules and/or infiltrates

12 (23.0)

Alveolar hemorrhage

6 (11.5)

Pleural effusion

2 (3.8)

Endobronchial lesion

1 (1.9)

Renal-related variables

Median 24-hour proteinuria (g)

0.90 (0.55 to 1.60)

Hematuria (>10 RBC/HPF)

39 (75.0)

Median creatinine (μmol/l)

137.0 (80.0 to 350.0)

Mean creatinine clearance (ml/minute/1.73 m2)

65.7 ± 41.7

Dialysis dependent

8 (15.4)

Actual therapy

Patients without treatment

27 (51.9)

Prednisolone and cyclophosphamide

13 (25.0)

Prednisolone only

7 (13.5)

Plasmapheresis

6 (11.5)

Mean number of plasmapheresis sessions

9.33 ± 1.50

Methotrexate

1 (1.9)


Data presented as n (%), median (interquartile range) or mean ± standard deviation. ANCA, antineutrophil cytoplasmic antibodies; BVAS, Birmingham Vasculitis Activity Score; HPF, high-power field; RBC, red blood cells.

de Souza et al. Arthritis Research & Therapy 2013 15:R104   doi:10.1186/ar4284

Open Data